Table 2.
Pathway activity score differences between patients with and without clinical benefit.
| Pathway | Clinical Benefit (Mean (Range)) | No Clinical Benefit (Mean (Range)) | Difference |
|---|---|---|---|
| AR | 57.5 (31.7–71.9) | 52.8 (29.6–71.9) | p = 0.02 |
| Notch | 68.1 (58.8–79.3) | 64.8 (52.2–76.0) | p = 0.05 |
| MAPK | 63.0 (47.8–73.2) | 66.4 (50.7–84.9) | p = 0.051 |
| TGFβ | 66.2 (49.2–74.5) | 68.2 (57.5–78.5) | p = 0.26 |
| ER | 35.3 (11.3–45.3) | 33.3 (16.7–44.9) | p = 0.097 |
| HH | 25.9 (11.3–38.9) | 26.8 (13.4–35.0) | p = 0.44 |
| PI3K 1 | 16.7 (6.5–32.9) | 16.7 (6.5–28.8) | p = 0.88 |
| SRD5A1 expression 2 | 1.45 (−1.46–3.67) | 0.42 (−1.18–2.39) | p < 0.001 |
Abbreviations: AR: androgen receptor pathway; Notch: Notch signaling pathway; MAPK: mitogen-activated protein kinase pathway; TGFβ: transforming growth factor beta signaling pathway; ER: estrogen receptor pathway; HH: hedgehog signaling pathway; PI3K: phosphoinositide 3-kinase pathway. 1. PI3K, as the inverse of Forkhead Box-O (FOXO) signaling, in the absence of oxidative stress. 2. Log-transformed value of SRD5A1 expression normalized to HPRT1.